Pd-l1 expression in medullary thyroid carcinoma and its association with clinicopathological findings
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 38 (2) , 1-8
Abstract
Objective: Medullary thyroid carcinoma (MTC) is a rare tumor originating from parafollicular C cells. It has more aggressive biologic behavior than differentiated thyroid carcinomas, and it is insensitive to treatment with radioactive iodine. Vandetanib and cabozantinib are the newly approved tyrosine kinase inhibitors in advanced stages, but novel effective systemic therapeutics could be crucial and needed for the clinical management of these patients. We aimed to evaluate the Programmed death-ligand 1 (PD-L1) expression, which is a novel immunotherapy target, in our MTC cohort, and determine whether it has an association with clinical and pathological features.Keywords
This publication has 19 references indexed in Scilit:
- CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapyHistopathology, 2017
- Very low expression of PD-L1 in medullary thyroid carcinomaEndocrine-Related Cancer, 2017
- Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and RecurrenceThyroid®, 2017
- Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2017
- Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumorsInvestigational New Drugs, 2016
- Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2016
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variantsOncotarget, 2016
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- BRAF V600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell InfiltrationThyroid®, 2014
- Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patientsClinical Endocrinology, 1998